Sichuan Hebang Biotechnology (SHSE:603077) Shareholders Have Lost 21% Over 1 Year, Earnings Decline Likely the Culprit
Sichuan Hebang Biotechnology (SHSE:603077) Shareholders Have Lost 21% Over 1 Year, Earnings Decline Likely the Culprit
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if you buy individual stocks, you can do both better or worse than that. Investors in Sichuan Hebang Biotechnology Corporation Limited (SHSE:603077) have tasted that bitter downside in the last year, as the share price dropped 23%. That's disappointing when you consider the market declined 8.0%. On the bright side, the stock is actually up 9.5% in the last three years. Shareholders have had an even rougher run lately, with the share price down 17% in the last 90 days. This could be related to the recent financial results - you can catch up on the most recent data by reading our company report.
被动投资指数基金是确保自己的回报与整个市场大致相匹配的好方法。但是,如果你买入个股,你的表现可能比这更好或更差。去年,由于股价下跌了23%,四川和邦生物科技股份有限公司(SHSE: 603077)的投资者已经尝到了这种痛苦的下行空间。考虑到市场下跌了8.0%,这真是令人失望。好的一面是,股票实际上是 向上 在过去三年中为9.5%。股东们最近的表现更加艰难,股价在过去90天中下跌了17%。这可能与最近的财务业绩有关——您可以通过阅读我们的公司报告来了解最新的数据。
Since Sichuan Hebang Biotechnology has shed CN¥661m from its value in the past 7 days, let's see if the longer term decline has been driven by the business' economics.
由于四川和邦生物科技在过去7天内已从其市值下跌了6.61亿元人民币,让我们看看长期下跌是否是由该企业的经济推动的。
To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).
用本杰明·格雷厄姆的话来说:从短期来看,市场是一台投票机器,但从长远来看,它是一台称重机。研究市场情绪如何随着时间的推移而变化的一种方法是研究公司股价与其每股收益(EPS)之间的相互作用。
Unhappily, Sichuan Hebang Biotechnology had to report a 71% decline in EPS over the last year. The share price fall of 23% isn't as bad as the reduction in earnings per share. So despite the weak per-share profits, some investors are probably relieved the situation wasn't more difficult.
不幸的是,四川和邦生物科技不得不报告去年每股收益下降了71%。股价下跌23%还不如每股收益的下降那么严重。因此,尽管每股利润疲软,但一些投资者可能会松一口气,情况并没有变得更加困难。
You can see below how EPS has changed over time (discover the exact values by clicking on the image).
你可以在下面看到 EPS 是如何随着时间的推移而变化的(点击图片发现确切的值)。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240514/0-b02a864bc9fa693a6fc1eb452aeaf3a9-0-ffe657620273dc649a7248fff94fa281.png/big)
It might be well worthwhile taking a look at our free report on Sichuan Hebang Biotechnology's earnings, revenue and cash flow.
不妨看看我们关于四川和邦生物科技的收益、收入和现金流的免费报告。
A Different Perspective
不同的视角
We regret to report that Sichuan Hebang Biotechnology shareholders are down 21% for the year. Unfortunately, that's worse than the broader market decline of 8.0%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Longer term investors wouldn't be so upset, since they would have made 2%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. It's always interesting to track share price performance over the longer term. But to understand Sichuan Hebang Biotechnology better, we need to consider many other factors. Even so, be aware that Sichuan Hebang Biotechnology is showing 1 warning sign in our investment analysis , you should know about...
我们遗憾地报告,四川和邦生物科技的股东今年下跌了21%。不幸的是,这比整个市场8.0%的跌幅还要严重。话虽如此,在下跌的市场中,一些股票不可避免地会被超卖。关键是要密切关注基本发展。长期投资者不会那么沮丧,因为他们本可以在五年内每年赚2%。如果基本面数据继续显示长期可持续增长,那么当前的抛售可能是一个值得考虑的机会。长期跟踪股价表现总是很有意思的。但是,要更好地了解四川和邦生物科技,我们需要考虑许多其他因素。即便如此,请注意,四川和邦生物科技在我们的投资分析中显示了1个警告信号,您应该知道...
But note: Sichuan Hebang Biotechnology may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).
但请注意:四川和邦生物科技可能不是最好的买入股票。因此,来看看这份过去盈利增长(以及进一步增长预测)的有趣公司的免费清单。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。